Clinical trials: Chiari Malformation Type 2
Actinic Keratosis
Safety and Toleration of PEP005 Topical Gel When Applied to a Treatment Area of up to 100cm2
Study Hypothesis: Safety and Tolerability will differ when treating multiple contiguous 25 cm2 treatment areas, as compared to individual 25 cm2 treatment areas.
- Trial name
- NCT00659893
- Testing
- PEP005 Topical gel
- Where
- 13 sites in United States, Australia
- Volunteers
- 64 people
- Sponsor
- Peplin
Articular Cartilage Lesion of the Femoral Condyle
Efficacy and Safety Study of co.Don Chondrosphere to Treat Cartilage Defects
This is a prospective, phase III, multicenter, open label, randomised clinical trial of co.don chondrosphere®, a three-dimensional autologous chondrocyte transplantation product (ACT3D-CS)compared to the procedure of…
- Trial name
- NCT01222559
- Testing
- co.don chondrosphere®, Microfracture
- Where
- 12 sites in Germany, Poland
- Volunteers
- 102 people
- Sponsor
- co.don AG
Actinic Keratosis
Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest
The objective of the trial is to investigate efficacy and safety of ingenol mebutate gel for actinic keratosis applied to large treatment areas once daily for three consecutive days on face, scalp or chest.
- Trial name
- NCT02361216
- Testing
- Ingenol Mebutate, Vehicle
- Where
- United States
- Volunteers
- 729 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Actinic Keratoses
Single-Center Study Evaluating Systemic Exposure and Safety of KX2-391 Ointment 1% on the Face or Balding Scalp in Subjects With Actinic Keratosis
This Phase I study is designed to evaluate the systemic exposure and safety of KX2-391 Ointment in adult subjects when applied to an area of skin containing at least 5 clinically typical, visible, and discrete Actinic Keratosis…
- Trial name
- NCT03575780
- Testing
- KX2-391 Ointment 1%
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Athenex, Inc.